| 前收市價 | 37.72 |
| 開市 | 0.00 |
| 買盤 | 0.00 x 無 |
| 賣出價 | 0.00 x 無 |
| 今日波幅 | 0.00 - 0.00 |
| 52 週波幅 | |
| 成交量 | |
| 平均成交量 | 351 |
| 市值 | 52.026M |
| Beta 值 (5 年，每月) | 0.41 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.03 |
| 業績公佈日 | 2024年8月07日 - 2024年8月12日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
ZacksThe Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics are part of the Zacks top Analyst Blog.
ZacksIonis (IONS), Biogen Down on Ending Development of ALS Drug
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
- Reuters
REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patients in an early-to-mid stage study. Shares of Biogen and Ionis were each down nearly 2% in premarket trading. This marks another setback in the search for new treatments for ALS, a rare neurodegenerative disease that affects the voluntary control of limbs and leads to breathing trouble.
